Pacira BioSciences, Inc. (NASDAQ:PCRX) — Market Cap & Net Worth

$1.00 Billion USD · Rank #8752

Market Cap & Net Worth: Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) has a market capitalization of $1.00 Billion ($1.00 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8752 globally and #2500 in its home market, demonstrating a 1.85% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pacira BioSciences, Inc.'s stock price $26.41 by its total outstanding shares 39347924 (39.35 Million). See reinvestment intensity of Pacira BioSciences, Inc. to understand how much of operating cash flow is reinvested back into capital assets.

Pacira BioSciences, Inc. Market Cap History: 2015 to 2026

Pacira BioSciences, Inc.'s market capitalization history from 2015 to 2026. Data shows change from $3.02 Billion to $1.04 Billion (-4.02% CAGR).

Index Memberships

Pacira BioSciences, Inc. is a constituent of 4 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
NASDAQ Health Care IXHC	$2.46 Trillion	0.04%	#256 of 976
NASDAQ Composite IXIC	$40.26 Trillion	0.00%	#949 of 3165
NASDAQ Biotechnology NBI	$1.72 Trillion	0.06%	#147 of 263
S&P Small-Cap 600 Index SML	$1.60 Trillion	0.10%	#465 of 602

Weight: Pacira BioSciences, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Pacira BioSciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Pacira BioSciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

1.40x

Pacira BioSciences, Inc.'s market cap is 1.40 times its annual revenue

Industry average: 0.63x Higher than industry average

Latest Price to Earnings (P/E) Ratio

144.77x

Pacira BioSciences, Inc.'s market cap is 144.77 times its annual earnings

Industry average: 4.55x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$1.27 Billion	$276.37 Million	-$37.95 Million	4.60x	N/A
2017	$1.80 Billion	$286.63 Million	-$42.61 Million	6.27x	N/A
2018	$1.69 Billion	$337.28 Million	-$471.00K	5.02x	N/A
2019	$1.78 Billion	$421.03 Million	-$11.02 Million	4.23x	N/A
2020	$2.35 Billion	$429.65 Million	$145.52 Million	5.48x	16.18x
2021	$2.37 Billion	$541.53 Million	$41.98 Million	4.37x	56.40x
2022	$1.52 Billion	$666.82 Million	$15.91 Million	2.28x	95.49x
2023	$1.33 Billion	$674.98 Million	$41.95 Million	1.97x	31.64x
2024	$741.31 Million	$700.97 Million	-$99.56 Million	1.06x	N/A
2025	$1.02 Billion	$726.41 Million	$7.03 Million	1.40x	144.77x

Competitor Companies of PCRX by Market Capitalization

Companies near Pacira BioSciences, Inc. in the global market cap rankings as of August 1, 2026.

Key companies related to Pacira BioSciences, Inc. by market ranking:

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#503	Takeda Pharmaceutical Co Ltd ADR	NYSE:TAK	$52.60 Billion	$16.65
#528	Jiangsu Hengrui Medicine Co Ltd	SHG:600276	$50.48 Billion	CN¥54.08
#550	GALDERMA GROUP AG	NYSE:GALDY	$48.78 Billion	$43.60
#619	Takeda Pharmaceutical Company Limited	F:TKDA	$43.60 Billion	€15.50

Pacira BioSciences, Inc. Historical Marketcap From 2015 to 2026

Between 2015 and today, Pacira BioSciences, Inc.'s market cap moved from $3.02 Billion to $ 1.04 Billion, with a yearly change of -4.02%.

Year	Market Cap	Change (%)
2026	$1.04 Billion	+2.05%
2025	$1.02 Billion	+37.37%
2024	$741.31 Million	-44.16%
2023	$1.33 Billion	-12.61%
2022	$1.52 Billion	-35.83%
2021	$2.37 Billion	+0.55%
2020	$2.35 Billion	+32.10%
2019	$1.78 Billion	+5.30%
2018	$1.69 Billion	-5.76%
2017	$1.80 Billion	+41.33%
2016	$1.27 Billion	-57.94%
2015	$3.02 Billion	--

End of Day Market Cap According to Different Sources

On Aug 1st, 2026 the market cap of Pacira BioSciences, Inc. was reported to be:

Source	Market Cap
Yahoo Finance	$1.00 Billion USD
MoneyControl	$1.00 Billion USD
MarketWatch	$1.00 Billion USD
marketcap.company	$1.00 Billion USD
Reuters	$1.00 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Pacira BioSciences, Inc.

NASDAQ:PCRX USA Drug Manufacturers - Specialty & Generic

Market Cap

$1.04 Billion

Market Cap Rank

#8752 Global

#2500 in USA

Share Price

$26.41

Change (1 day)

-2.08%

52-Week Range

$19.16 - $27.22

All Time High

$81.64